MapLight Therapeutics, Inc. MPLT Employee Related — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about MapLight Therapeutics, Inc. 's employee related — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MapLight Therapeutics, Inc. 's employee related — research and development expense?
- MapLight Therapeutics, Inc. (MPLT) reported employee related — research and development expense of $15.99M in Q1 2026.
- How has MapLight Therapeutics, Inc. 's employee related — research and development expense changed year-over-year?
- MapLight Therapeutics, Inc. 's employee related — research and development expense increased by 126.9% year-over-year, from $7.05M to $15.99M.
- What does employee related — research and development expense mean?
- This metric represents the portion of total research and development expenditures specifically allocated to personnel costs, including salaries, benefits, and stock-based compensation for scientific and clinical staff. It reflects the company's investment in human capital required to advance its drug pipeline and clinical trial programs. Monitoring this figure helps investors assess the company's commitment to internal innovation and the scalability of its clinical development operations.